Compass Therapeutics to Participate in Upcoming September Investor Events

About this update from Compass Therapeutics, Inc.

BOSTON , Aug. 26, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of September. Details are as follows: Citi’s 2025 Biopharma Back to School Conference Location: Boston, MA Date: Tuesday, September 2, 2025 Cantor Global Healthcare Conference Location: New York, NY Date: Wednesday, September 3, 2025 Time: 2:10 PM ET Webcast Link: https://cmpx.info/cantor H.C. Wainwright 27 th Annual Global Investment Conference Location: New York, NY Date: Monday, September 8, 2025 Time: 11 AM ET Webcast Link: https://journey.ct.events/view/c21a88e1-14c6-46cd-85b8-dbfa550d85a1 Morgan Stanley 23 rd Annual Global Healthcare Conference Location: New York, NY Date: Tuesday, September 9, 2025 Time: 5:35 PM ET Webcast Link: https://cc.webcasts.com/morg007/090825a_js/?entity=89_N2MHE8Q Virtual/Replay availability: Presentations will be archived for 90 days on Compass’ Events page. About Compass Therapeutics Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass has built a robust pipeline of novel product candidates designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. The company plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts . Investor Contact [email protected] Media Contact Anna Gifford , Chief of Staff [email protected] 617-500-8099 Source: Compass Therapeutics

View stock analysis, news, and events for Compass Therapeutics, Inc.